TL;DR
This paper presents a novel hydrogel sponge loaded with lyophilized apoptotic vesicles (apoVs) that acts as a rapid and effective hemostat for severe bleeding, even in patients with coagulopathy. This apoV-hydrogel sponge demonstrates superior performance to commercial hemostats in animal models, offering a promising solution for traumatic hemorrhage.
What Problem Does This Paper Address?
Uncontrolled bleeding from traumatic injuries is a major cause of mortality, and this problem is significantly exacerbated when the patient also suffers from coagulopathy, a condition where blood clotting is impaired. Existing hemostatic agents often struggle to effectively control severe bleeding in these complex scenarios. Extracellular vesicles (EVs), particularly apoptotic vesicles (apoVs), have shown potential for promoting blood clotting due to their expression of tissue factor (TF) and phosphatidylserine (PS). However, challenges with low yield, difficult storage, and the lack of suitable carriers have limited their clinical application. This research aims to overcome these limitations by developing a stable, portable, and highly effective hemostatic system using apoVs.
Methods
The researchers developed a multi-step approach:
- Optimized ApoV Production: They optimized the induction of apoptosis in human umbilical cord mesenchymal stem cells (UCMSCs) using staurosporine (STS) to maximize the yield and expression of TF and PS on the resulting apoVs.
- Lyophilization of ApoVs: ApoVs were lyophilized (freeze-dried) to ensure long-term stability at room temperature, addressing storage and transport challenges.
- Hydrogel Sponge Fabrication: A novel adhesive hydrogel sponge (apoV-HS) was created by combining phenylboronic acid-grafted oxidized hyaluronic acid (PBA-HA) and poly(vinyl alcohol) (PVA). This hydrogel was designed to be injectable, compressible, and adhesive.
- ApoV Encapsulation: The lyophilized apoVs were incorporated into the PBA-HA/PVA hydrogel, followed by another lyophilization step to create the final apoV-HS.
- In Vitro and In Vivo Testing: The apoV-HS was rigorously tested for its hemostatic efficacy, biocompatibility, and stability. This included clotting assays, animal models of liver and femoral artery bleeding in rats and rabbits (including heparinized models to simulate coagulopathy), and histological analysis.
Datasets
Not discussed in the paper. The study primarily relies on experimental data generated from cell cultures and animal models.
Key Insights and Ideas
- ApoVs as Superior Clotting Agents: The study highlights that apoVs, derived from mesenchymal stem cells, possess a significantly higher expression of TF and PS compared to exosomes, leading to superior procoagulant efficiency.
- TF and PS Dependence: The procoagulant activity of apoVs is mechanistically linked to their surface expression of TF and PS, initiating the extrinsic coagulation pathway. This activity is independent of hemocytes and circulating microparticles.
- Lyophilization for Stability and Portability: Lyophilizing apoVs and the hydrogel sponge provides a stable, room-temperature-storable, and easily transportable hemostatic agent, overcoming critical limitations of previous EV-based therapies.
- Adhesive Hydrogel for Enhanced Hemostasis: The PBA-HA/PVA hydrogel's adhesive properties allow the apoV-HS to firmly attach to wound surfaces, even in the presence of significant bleeding, which is crucial for effective hemostasis.
- Injectable and Compressible Nature: The hydrogel sponge's ability to be compressed and injected makes it suitable for application in deep and irregular wounds, expanding its potential use cases.
Key Results
- Enhanced ApoV Production: Optimized STS treatment yielded apoVs with significantly higher TF and PS expression and improved yield.
- Stable Lyophilized ApoVs: Lyophilized apoVs maintained their bioactivity and procoagulant properties for at least 2 months at room temperature.
- Effective Hemostasis in Animal Models:
- In rat liver bleeding models, apoV-HS stopped bleeding significantly faster (1.375 ± 0.25 min) and with less blood loss compared to commercial hemostats (Avitene™, Surgifoam®).
- In rat femoral artery/vein bleeding models, apoV-HS also demonstrated superior hemostatic performance, with significantly reduced bleeding time and blood loss.
- In heparinized rabbit femoral artery bleeding models, apoV-HS achieved hemostasis in 2.5±0.5774 min with significantly less blood loss compared to controls.
- Superior Biocompatibility: In vitro and in vivo biocompatibility tests showed that apoV-HS is non-toxic and elicits minimal inflammatory response, even in injured liver tissues.
- Rapid ApoV Release: ApoV-HS exhibited a rapid release of apoVs, with nearly 25% released within 1 minute and almost complete release within 1 hour, ensuring immediate and sustained hemostatic action.
Limitations and Future Work
The authors acknowledge several limitations and suggest future directions:
- Larger Animal Models: Further evaluation in larger animal models, such as porcine puncture wounds, is recommended to obtain more precise data for potential clinical translation.
- Long-Term Storage at RT: While stability for 2 months at RT was demonstrated, longer-term storage studies are needed to fully verify its validity as a ready-to-use clinical hemostat.
- Alternative Apoptosis Induction Methods: The study used staurosporine (STS), a chemotherapy drug, to induce apoptosis. Future research should explore alternative, potentially more clinically relevant methods like mechanical forces for inducing MSC apoptosis to acquire superior apoVs.
- Clinical Translation: While promising, the transition to clinical application will require extensive further research and regulatory approval.
Summary updated